RU2016104398A3 - - Google Patents

Download PDF

Info

Publication number
RU2016104398A3
RU2016104398A3 RU2016104398A RU2016104398A RU2016104398A3 RU 2016104398 A3 RU2016104398 A3 RU 2016104398A3 RU 2016104398 A RU2016104398 A RU 2016104398A RU 2016104398 A RU2016104398 A RU 2016104398A RU 2016104398 A3 RU2016104398 A3 RU 2016104398A3
Authority
RU
Russia
Application number
RU2016104398A
Other languages
Russian (ru)
Other versions
RU2016104398A (ru
RU2676303C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016104398A publication Critical patent/RU2016104398A/ru
Publication of RU2016104398A3 publication Critical patent/RU2016104398A3/ru
Application granted granted Critical
Publication of RU2676303C2 publication Critical patent/RU2676303C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A61F9/00823—Laser features or special beam parameters therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
RU2016104398A 2013-07-11 2014-07-10 Использование антагониста vegf для лечения ретролентальной фиброплазии RU2676303C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845073P 2013-07-11 2013-07-11
US61/845,073 2013-07-11
PCT/IB2014/063003 WO2015004626A2 (en) 2013-07-11 2014-07-10 Use of a vegf antagonist in treating retinopathy of prematurity

Publications (3)

Publication Number Publication Date
RU2016104398A RU2016104398A (ru) 2017-08-16
RU2016104398A3 true RU2016104398A3 (OSRAM) 2018-05-31
RU2676303C2 RU2676303C2 (ru) 2018-12-27

Family

ID=51211284

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016104398A RU2676303C2 (ru) 2013-07-11 2014-07-10 Использование антагониста vegf для лечения ретролентальной фиброплазии

Country Status (14)

Country Link
US (1) US20160159893A1 (OSRAM)
EP (1) EP3019527A2 (OSRAM)
JP (1) JP2016523956A (OSRAM)
KR (1) KR20160030504A (OSRAM)
CN (1) CN105377890A (OSRAM)
AR (1) AR096893A1 (OSRAM)
AU (3) AU2014288847A1 (OSRAM)
BR (1) BR112016000282A2 (OSRAM)
CA (1) CA2917813A1 (OSRAM)
HK (1) HK1221231A1 (OSRAM)
MX (1) MX2016000385A (OSRAM)
RU (1) RU2676303C2 (OSRAM)
TW (1) TW201536317A (OSRAM)
WO (1) WO2015004626A2 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CA2748765C (en) 2009-07-06 2014-07-22 Akebia Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
MX387804B (es) 2015-09-23 2025-03-19 Aerpio Therapeutics Inc Metodos para tratar presion intraocular con activadores de tie-2
ES2903397T3 (es) 2015-12-30 2022-04-01 Marshall Univ Research Corporation Composiciones y métodos para tratar la retinopatía
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン，エルエルシー Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
NZ601544A (en) * 2003-08-27 2013-11-29 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
WO2006113665A2 (en) * 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
CN101909694A (zh) * 2007-11-07 2010-12-08 人类起源公司 脐带血在治疗早产并发症中的用途
WO2010045506A2 (en) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Sustained drug delivery system
CN102272148A (zh) * 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
WO2010127029A1 (en) * 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"
EP2768504A1 (en) * 2011-10-20 2014-08-27 Avienne Pharmaceuticals GmbH Compositions for controlling vascularization in ophthalmological and dermatological diseases
US10548841B2 (en) * 2012-08-21 2020-02-04 Opko Pharmaceuticals, Llc Liposome formulations

Also Published As

Publication number Publication date
AU2014288847A1 (en) 2016-01-28
CN105377890A (zh) 2016-03-02
US20160159893A1 (en) 2016-06-09
TW201536317A (zh) 2015-10-01
JP2016523956A (ja) 2016-08-12
CA2917813A1 (en) 2015-01-15
WO2015004626A3 (en) 2015-05-28
RU2016104398A (ru) 2017-08-16
AU2017204326A1 (en) 2017-07-13
WO2015004626A2 (en) 2015-01-15
AR096893A1 (es) 2016-02-03
KR20160030504A (ko) 2016-03-18
EP3019527A2 (en) 2016-05-18
RU2676303C2 (ru) 2018-12-27
BR112016000282A2 (pt) 2017-12-12
MX2016000385A (es) 2016-04-29
AU2019206000A1 (en) 2019-08-01
HK1221231A1 (zh) 2017-05-26

Similar Documents

Publication Publication Date Title
BR112016012521A2 (OSRAM)
BR112016005220A2 (OSRAM)
BR112015007533A2 (OSRAM)
BR102016010778A2 (OSRAM)
BR112014018502A2 (OSRAM)
BR112014019326A2 (OSRAM)
BR112014018480A2 (OSRAM)
BR112014018516A2 (OSRAM)
BR112014020341A2 (OSRAM)
BR112014017855A2 (OSRAM)
BR112016007979A2 (OSRAM)
BR112014021878A2 (OSRAM)
BR112014018468A2 (OSRAM)
BR112014017901A2 (OSRAM)
BR112014019204A2 (OSRAM)
BR112014018207A2 (OSRAM)
RU2016104398A3 (OSRAM)
BR112016000222A2 (OSRAM)
BR112015015948A2 (OSRAM)
BR112016004477A2 (OSRAM)
BR112014018578A2 (OSRAM)
BR112014018483A2 (OSRAM)
BR112016000122A2 (OSRAM)
BR112014017601A2 (OSRAM)
BR112015015312A2 (OSRAM)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200711